Related Experiment Video

Updated: Mar 21, 2026

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.4K

NLRC5/MHC class I transactivator is a target for immune evasion in cancer

Sayuri Yoshihama1, Jason Roszik2, Isaac Downs3

  • 1Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, College Station, TX 77843; Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan;

Proceedings of the National Academy of Sciences of the United States of America
|May 11, 2016
PubMed

Insights

Cancer cells evade immune detection by downregulating MHC class I. NLRC5 (MHC class I transactivator) is crucial for MHC class I expression and its alterations impact T-cell response and patient survival.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Cancer cells employ immune evasion strategies to survive and grow.
  • Loss of MHC class I expression is a common immune escape mechanism in cancer.
  • The molecular mechanisms underlying MHC class I downregulation remain largely unknown.

Purpose of the Study:

  • To investigate the role of MHC class I transactivator (CITA), also known as NLRC5, in cancer immune evasion.
  • To determine the correlation between NLRC5 expression and MHC class I pathway components in various cancer types.
  • To assess the clinical significance of NLRC5 as a prognostic biomarker and therapeutic target.

Main Methods:

  • Analysis of NLRC5 expression in 21 tumor types.
  • Correlation studies between NLRC5, MHC class I, cytotoxic T-cell markers, and antigen-presentation pathway genes.
  • Examination of epigenetic and genetic alterations (promoter methylation, copy number loss, somatic mutations) in NLRC5 and related genes.
  • Association analysis of NLRC5 expression with CD8(+) T-cell activation and patient survival.

Main Results:

  • NLRC5 expression strongly correlated with MHC class I, cytotoxic T-cell markers, and antigen-presentation pathway genes (LMP2/LMP7, TAP1, β2-microglobulin) across 21 cancer types.
  • Epigenetic and genetic alterations in NLRC5 were prevalent and linked to impaired MHC class I pathway function.
  • NLRC5 expression was significantly associated with CD8(+) cytotoxic T-cell activation and improved patient survival in multiple cancers.

Conclusions:

  • The NLRC5-mediated MHC class I transactivation pathway is a target for cancer immune evasion.
  • NLRC5 alterations are common in cancer and impair anti-tumor immunity.
  • NLRC5 serves as a novel prognostic biomarker and potential therapeutic target for improving cancer patient outcomes.
Keywords:
CITAMHC class INLRC5cancerimmune evasion

More Related Videos

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.1K
Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production08:32

Dissecting Innate Immune Signaling in Viral Evasion of Cytokine Production

Published on: March 2, 2014

11.0K

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.2K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

3.0K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.1K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.9K